TY - JOUR
T1 - Synergistic Enhancement by Tumor Necrosis Factor of in Vitro Cytotoxicity-group from Chemotherapeutic Drugs Targeted at DNA Topoisomerase II
AU - Alexander, Richard B.
AU - Nelson, William G.
AU - Coffey, Donald S.
PY - 1987/5/1
Y1 - 1987/5/1
N2 - Recombinant human tumor necrosis factor (rHTNF) alone had no effect on L929 tumor cells at 100 units/ml for 20 h of continuous exposure. However, under the same conditions, rHTNF markedly enhanced the cytotoxicity of Adriamycin, actinomycin D, 4' -(9-acridinylamino)-methanesulfon-m-anisidide, teniposide (VM 26), and etoposide (VP 16), all targeted at DNA topoisomerase II. The rHTNF had a minimally enhancing effect on the cytotoxicity-group of bleomycin, hydroxyurea, and 1-β-D-arabinofuranosylcytosine and no effect on the cytotoxicity-group of cis-platinum, mitomycin C, vincristine, and vinblastine, all chemotherapeutic drugs with dose-related cytotoxic effects on L929 cells but mechanisms of action which do not appear to involve topoisomerase II. Treatment with rHTNF first and then topoisomerase-targeted drugs yielded no enhanced cytotoxicity-group, whereas pretreatment with drug followed by rHTNF yielded marked enhancement of cytotoxicity-group. Topoisomerases have previously been implicated in cell kill phenomena following treatment with certain chemotherapeutic agents [K. M. Tewey, et al. Science (Wash. DC), 226:466-468,1984). The data suggest that the lethality to the cell from topoisomerase-targeted drug treatment is increased by rHTNF in vitro. We suggest that rHTNF may be a useful adjuvant to this class of drugs which has well-known antitumor activity.
AB - Recombinant human tumor necrosis factor (rHTNF) alone had no effect on L929 tumor cells at 100 units/ml for 20 h of continuous exposure. However, under the same conditions, rHTNF markedly enhanced the cytotoxicity of Adriamycin, actinomycin D, 4' -(9-acridinylamino)-methanesulfon-m-anisidide, teniposide (VM 26), and etoposide (VP 16), all targeted at DNA topoisomerase II. The rHTNF had a minimally enhancing effect on the cytotoxicity-group of bleomycin, hydroxyurea, and 1-β-D-arabinofuranosylcytosine and no effect on the cytotoxicity-group of cis-platinum, mitomycin C, vincristine, and vinblastine, all chemotherapeutic drugs with dose-related cytotoxic effects on L929 cells but mechanisms of action which do not appear to involve topoisomerase II. Treatment with rHTNF first and then topoisomerase-targeted drugs yielded no enhanced cytotoxicity-group, whereas pretreatment with drug followed by rHTNF yielded marked enhancement of cytotoxicity-group. Topoisomerases have previously been implicated in cell kill phenomena following treatment with certain chemotherapeutic agents [K. M. Tewey, et al. Science (Wash. DC), 226:466-468,1984). The data suggest that the lethality to the cell from topoisomerase-targeted drug treatment is increased by rHTNF in vitro. We suggest that rHTNF may be a useful adjuvant to this class of drugs which has well-known antitumor activity.
UR - http://www.scopus.com/inward/record.url?scp=0023226456&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023226456&partnerID=8YFLogxK
M3 - Article
C2 - 2436763
AN - SCOPUS:0023226456
SN - 0008-5472
VL - 47
SP - 2403
EP - 2406
JO - Cancer Research
JF - Cancer Research
IS - 9
ER -